Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 12, Issue 7, 2014, Pages

[No Author Info available]

Author keywords

Bimuno ; gastro intestinal discomfort; GOS; health claims; galacto oligosaccharides

Indexed keywords

EID: 84938684582     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2014.3756     Document Type: Article

References (17)

1. Depeint F, Tzortzis G, Vulevic J, I'Anson K and Gibson GR, 2008 (claimed as proprietary by the applicant). Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomised, double-blind, crossover, placebo-controlled intervention study. American Journal of Clinical Nutrition, 87, 785–891.
2. Drakoularakou A, Tzortzis G, Rastall RA and Gibson GR, 2010 (claimed as proprietary by the applicant). A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea. European Journal of Clinical Nutrition, 64, 146–152.
3. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011. Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(12):2472, 13 pp. doi:10.2903/j.efsa.2011.2472
4. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2013. Scientific Opinion on the substantiation of a health claim related to Bimuno® GOS and reducing gastro-intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal 2013;11(6):3259, 10 pp. doi:10.2903/j.efsa.2013.3259
5. Evans BW, Clark WK, Moore DJ and Whorwell PJ, 2007. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database of Systematic Reviews, CD003960.
6. Goulas G, Tzortzis G and Gibson GR, 2007 (claimed as proprietary by the applicant). Development of a process for the production and purification of α- and β-galactooligosaccharides from Bifidobacterium bifidum NCIMB 41171. International Dairy Journal, 17, 648–656.
7. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ and Veldheuyzen van Zanten SJ, 2006. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology, 130, 1538–1551.
8. Searle LE, Best A, Nunez A, Salguero FJ, Johnson L, Weyer U, Dugdale AH, Cooley WA, Carter B, Jones G, Tzortzis G, Woodward MJ and La Ragione RM, 2009. A mixture containing galactooligosaccharide, produced by the enzymic activity of Bifidobacterium bifidum, reduces Salmonella enterica serovar Typhimurium infection in mice. Journal of Medical Microbiology, 58, 37–48.
9. Searle LE, Cooley WA, Jones G, Nunez A, Crudgington B, Weyer U, Dugdale AH, Tzortzis G, Woodward MJ and La Ragione RM, 2010. Purified galactooligosaccharide derived from a mixture produced by the enzymatic activity of Bifidobacterium bifidum reduced Salmonella Typhimurium adhesion and invasion in vitro and in vivo. Journal of Medical Microbiology, 59, 1428–1439.
10. Silk DB, Davis A, Vulevic J, Tzortzis G and Gibson GR, 2009 (claimed as proprietary by the applicant). Clinical trial: the effect of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Alimentary Pharmacology Therapeutics, 29, 508–518.
11. Tzortzis G, Vulevic J, Holliss M, Wilson J, de Angelis G, 2013, unpublished (claimed as proprietary by the applicant). Reducing the incidence and severity of abdominal discomfort with daily intake of 1.37g galactooligosaccharides from Bimuno: double blind, randomised clinical trial of efficacy.
12. Tzortzis G, Goulas AK, Gee JM and Gibson GR, 2005a (claimed as proprietary by the applicant). A novel galactooligosaccharide mixture increases the bifidoabcterial population numbers in a continuous in vitro fermentation system and in the proximal colonic contents of pigs in vivo. Journal of Nutrition, 135, 1726–1731.
13. Tzortzis G, Goulas AK and Gibson GR, 2005b (claimed as proprietary by the applicant). Synthesis of prebiotic galactooligosaccharides using whole cells of a novel strain, Bifidobacterium bifidum NCIMB 4117. Applied Microbiology and Biotechnology, 68, 412–416.
14. Tzortzis G, 2009. Development and functional properties of Bimuno®: a second-generation prebiotic mixture. Food Science and Technology Bulletin: Functional Foods, 6, 81–89.
15. Vulevic J, Drakoularakou A, Yaqoob P, Tzortzis G and Gibson GR, 2008 (claimed as proprietary by the applicant). Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosacharide mixture (B-GOS) in healthy elderly volunteers. American Journal of Clinical Nutrition, 88, 1438–1446.
16. Vulevic J, Juric A, Constabile A and Tzortzis G, undated and unpublished (claimed as proprietary by the applicant). A double blind, placebo controlled, randomised, single centred, crossover study to determine the effect of Bimuno® on abdominal bloating and related gut function parameters in healthy adults.
17. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ and Zinsmeister AR, 1999. Design of treatment trials for functional gastrointestinal disorders. Gut, 45 Suppl 2, II69–77.